Beyond A-Beta: New Approaches To Alzheimer’s
This article was originally published in Start Up
Executive Summary
The track record for anti-amyloid beta Alzheimer’s treatments has been dismal. If upcoming results from pivotal trials for bapineuzumab and solanezumab are disappointing, they won’t scuttle the approach completely, but much more attention would shift toward other targets. We highlight two targets that have gained more attention of late, extracellular tau and ApoE4, and a diverse group of scientists working to move their work forward.
You may also be interested in...
Alzheimer’s Research To Be More Collaborative, Better Funded Under National Plan
Most of the additional money will help support two trials – one for insulin as a treatment and one for crenezumab as a preventative. The Obama administration formally launched its national Alzheimer’s plan in the midst of a two-day meeting that underscored how little researchers know about the disease.
Investors Lend Satori $15 Million, Hoping It Converts To An Alzheimer's Treatment
The venture-backed Cambridge, Mass. firm says it can get its small-molecule gamma-secretase modulator into the clinic next year.
New Cambridge-Elan Centre To Focus On Alzheimer's With $10 Million From Elan
Ireland's Elan Corp. launches a $10 million center for neuroscience R&D with University of Cambridge academics.